Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. May 5, 2021; 12(3): 40-55
Published online May 5, 2021. doi: 10.4292/wjgpt.v12.i3.40
Published online May 5, 2021. doi: 10.4292/wjgpt.v12.i3.40
Overview of drug induced liver injury in Brazil: What is the role of public health policy on the evidence?
Matheus William Becker, Karin Hepp Schwambach, Michele Lunardelli, Carine Raquel Blatt, Graduate Program in Medicine-Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, RS, Brazil
Carine Raquel Blatt, Pharmacoscience Department, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, RS, Brazil
Author contributions: Becker MW, Lunardelli M, and Blatt CR collected the data and wrote the paper; Becker MW, Schwambach KH, Blatt CR wrote and revised the paper.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
PRISMA 2009 Checklist statement: The guidelines of the PRISMA 2009 statement have been adopted.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Matheus William Becker, MSc, Pharmacist, Graduate Program in Medicine-Hepatology, Federal University of Health Sciences of Porto Alegre, Sarmento Leite, 245 Street, Porto Alegre 90050-170, RS, Brazil. matheuswbecker@gmail.com
Received: November 25, 2020
Peer-review started: November 25, 2020
First decision: January 7, 2021
Revised: January 20, 2021
Accepted: April 25, 2021
Article in press: April 25, 2021
Published online: May 5, 2021
Processing time: 155 Days and 9.9 Hours
Peer-review started: November 25, 2020
First decision: January 7, 2021
Revised: January 20, 2021
Accepted: April 25, 2021
Article in press: April 25, 2021
Published online: May 5, 2021
Processing time: 155 Days and 9.9 Hours
Core Tip
Core Tip: Hepatotoxicity is the main cause of safety-related drug marketing withdrawals and could be responsible for irreversible and fatal injuries. A systematic review of Brazilian studies was found 32 studies and the hepatotoxicity ranged from one to 57%, led by isoniazid, rifampicin, and pyrazinamide. Few studies reported algorithm to assess causality and twenty-two different criteria for hepatotoxicity were found. Standardization of parameter of drug-induced liver injury and greater effort in pharmacovigilance could contribute to learn more about drug-induced liver injury’s epidemiology in Brazil.